president ceo – Ron Bercume http://ronbercume.com/ Fri, 25 Mar 2022 20:07:58 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://ronbercume.com/wp-content/uploads/2021/10/icon-23-120x120.png president ceo – Ron Bercume http://ronbercume.com/ 32 32 Univision hires Michael Schwimmer to lead global platform strategy https://ronbercume.com/univision-hires-michael-schwimmer-to-lead-global-platform-strategy/ Wed, 19 Jan 2022 20:27:42 +0000 https://ronbercume.com/univision-hires-michael-schwimmer-to-lead-global-platform-strategy/ Michael Schwimmer university Univision Communications continues to strengthen its leadership ranks and build momentum for its new, yet to launch global streaming platform. Today, the company announced that it has hired Michael Schwimmer as President, Global Platform Strategy and Revenue. It’s a newly created executive position, which he says complements his “re-engineered corporate leadership structure […]]]>

Univision Communications continues to strengthen its leadership ranks and build momentum for its new, yet to launch global streaming platform. Today, the company announced that it has hired Michael Schwimmer as President, Global Platform Strategy and Revenue. It’s a newly created executive position, which he says complements his “re-engineered corporate leadership structure ahead of the close of Univision’s previously announced merger with Televisa.”

Schwimmer, who will report directly to CEO Wade Davis, will centralize the company’s platform distribution, content offerings and sales opportunities that drive revenue growth.

“His extensive experience leading multicultural and AVOD offerings strategy and his proven track record in business transformations make him the ideal addition to our team, and his expertise and passion for increasing Spanish language representation in the media speaks to our company’s purpose,” Davis said.

Schwimmer will be responsible for capitalizing on more than 300,000 hours of Univision’s existing Spanish-language content to reach audiences around the world. He will also work closely with Pierluigi Gazzolo, President and Chief Transformation Officer, on global application distribution for the company’s two-tier unified streaming service, slated for launch in early 2022.

Schwimmer’s hiring follows Univision’s January addition of four high-level executives recruited for its global platform team.

Prior to joining Univision, Schwimmer was President of the Sling TV Group and Executive Vice President of DISH Media, where he managed all aspects of the Sling TV business, including strategy and performance, as well as overseeing sales activities. advertisement for DISH. He was previously executive vice president of international development, business and strategy at Sling TV, responsible for the company’s multicultural and AVOD DISH TV and Sling TV offerings.

Schwimmer is no stranger to Hispanic media. He led the cable network SíTV, which was rebranded nuvoTV in 2011 before merging with Fuse in 2015. He left his role as President and CEO of Fuse Media, leading the cross-platform entertainment media brand for multicultural youth which included Fuse and FM (Fuse Music

BELFB
) linear channels, video-on-demand (VOD) and over-the-top (OTT) apps in 2019, the year the company filed for Chapter 11 bankruptcy.

Schwimmer also led programming, marketing and media sales for DISH Network, playing a key role in launching DISH’s international programming business as well as the DISH Latino brand and services. Schwimmer serves on the board of the National Association of Television Program Executives (NATPE) and is a member of the NAACP Entertainment Industry Board of Advisors.

“Supporting the global Spanish-speaking community has been a personal passion of mine, so I’m thrilled to be a part of Wade’s compelling vision to bring high-quality Spanish-language content to this still underserved audience in an advanced streaming format. and user-friendly,” says Schwimmer. “I look forward to building on my experience and getting started with my new colleagues in the streaming space as we build on Univision’s content and create a truly unparalleled global offering.”

]]>
Credit Union West Employees Donate to Rescue Group | Business https://ronbercume.com/credit-union-west-employees-donate-to-rescue-group-business/ Sat, 08 Jan 2022 08:00:00 +0000 https://ronbercume.com/credit-union-west-employees-donate-to-rescue-group-business/ In their last donation to EmployeesCARE in 2021, Credit Union West employees donated $ 5,257.50 to United Animal Friends, a non-profit animal rescue organization. United Animal Friends was chosen because of their ongoing work to find forever pet homes in Yavapai County. United Animal Friends is a non-profit, volunteer group that provides rescuing resources and […]]]>


In their last donation to EmployeesCARE in 2021, Credit Union West employees donated $ 5,257.50 to United Animal Friends, a non-profit animal rescue organization. United Animal Friends was chosen because of their ongoing work to find forever pet homes in Yavapai County.

United Animal Friends is a non-profit, volunteer group that provides rescuing resources and services to animals and those who care for them in Yavapai County. In addition to finding homes for the animals, the group also runs impactful programs such as low-cost sterilization and sterilization procedures and a community pet food bank, and provides funds for medical care for the animals. ’emergency.

Since its founding in 2003, United Animal Friends have placed over 6,000 pets in loving homes, helped spay or neuter over 20,000 cats and dogs, provided over 400,000 pounds of pet food for families. who could not afford to feed their pets, and funded more than 1,000 emergency veterinary services.

To support their efforts, executives at Credit Union West presented Joellyn Nusbaum, president of United Animal Friends, with a donation check on December 29 at their Prescott branch.

“This donation will help house, feed and care for countless pets over the coming year,” Nusbaum said. “We are very grateful that we can continue to provide these services to residents of Yavapai County and their pets. “

This charitable donation was made possible through Credit Union West’s employee-funded program called EmployeesCARE. The program raises funds for a local nonprofit organization selected by employees each quarter. In 2021, President and CEO Karen Roch challenged employees to increase donations and help nonprofits struggling with the pandemic by providing her own personal funds to match the program donation each quarter. .

“I am very proud of our employees who continue to take on this challenge throughout the year,” said Roch. “Credit Union West is honored to join United Animal Friends’ mission to help animals and their caregivers. “

This is the fourth and final donation from Credit Union West employees in 2021, totaling more than $ 18,000. Credit union staff hope to raise even more funds in 2022.

Anyone interested in donating or volunteering with United Animal Friends can find more information and resources at unitedanimalfriends.org.

TP


]]>
Caliber Associates Hires Development Director for Coherus BioSciences https://ronbercume.com/caliber-associates-hires-development-director-for-coherus-biosciences/ Thu, 23 Dec 2021 13:41:33 +0000 https://ronbercume.com/caliber-associates-hires-development-director-for-coherus-biosciences/ December 23, 2021 – based in San Diego, CA Caliber Associates recently appointed Theresa LaVallee as Director of Development at Coherus BioSciences in Redwood City, California. Dr. LaVallee will be a member of the company’s management team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus. […]]]>


December 23, 2021 – based in San Diego, CA Caliber Associates recently appointed Theresa LaVallee as Director of Development at Coherus BioSciences in Redwood City, California. Dr. LaVallee will be a member of the company’s management team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus.

“Theresa is a great addition to Coherus at a time when we are increasingly focusing on our immuno-oncology pipeline, particularly combinations with toripalimab, our PD-1 inhibitor,” said Mr. Lanfear. “She is a seasoned executive who has a proven track record in the end-to-end discovery and development of cancer drugs and diagnostics. With her scientific and regulatory expertise, she will play an essential role in the growth of our development capacities in immuno-oncology.

Dr. LaVallee brings over 25 years of experience in drug discovery and development. Most recently, she was Vice President, Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy, where she provided scientific leadership on clinical strategy for the development of novel immuno-oncology therapies and helped establish the clinical, translational and regulatory organization of the institute. Previously, she held senior positions at Kolltan Pharma and Celldex Therapeutics. From 2008 to 2013, she was a member of the AstraZeneca Immuno-Oncology team (MedImmune) developing checkpoint inhibitors and associated diagnostics. Dr. LaVallee received her PhD from the University of California, Los Angeles and her BA from the University of California, Santa Barbara.

“Coherus’ principal active ingredient in immuno-oncology, toripalimab, establishes a convincing clinical profile in late stage trials,” said Dr. LaVallee. “PD-1 inhibitors such as toripalimab are expected to play a fundamental long-term role in the development of immuno-oncology drugs as the backbone of new combination therapies. I look forward to working with the Coherus team and with the company’s world-class scientific advisory board to help Coherus become a leader in immuno-oncology and advance new treatments for cancer patients.

Related: Caliber Associates Hires Human Resources Director For INOVIO Pharmaceuticals

Coherus is a commercial-stage biopharmaceutical company whose mission is to increase access to cost-effective medicines that can have a major impact on the lives of patients and achieve significant savings for the healthcare system. Coherus’ strategy is to build a leading immuno-oncology franchise in the United States and Canada funded by cash generated from its biosimilars business activity.

Life sciences recruiters

Caliber Associates, founded in 1988, focuses exclusively on the life sciences industry. The company’s executives are highly experienced research professionals and biopharmaceutical executives who bring more than 70 years of industry experience. Caliber Associates has partnered with over 150 leading companies and performed over 700 research, placing strategic leaders with broad therapeutic and functional reach. The company has offices in San Diego, the New York subway, and Boston / Cambridge, MA.


Leadership in a post-Covid world

In this brand new episode of “Talent Talks,” Hunt Scanlon Media host Rob Adams is joined by Steve Hochberg, CEO of Caliber Associates. In this podcast, Hochberg explains how COVID-19 has changed the expectations of leaders, then explains how leaders can promote and maintain the culture as employees return to the workplace. Listen now!


Recent positions the company has held include Scientific Director of GentiBio, Vice President of Project Management at Locanabio and CEO of Caraway Therapeutics.

Steven Hochberg, Founder and CEO of the Research Firm, Focuses on Recruiting CEOs, Board Members, C-Level and Strategic Teams for Emerging Life Science Companies and Global Biopharmaceutical Companies . It brought together a small team of highly experienced and results-oriented research professionals. Prior to his research career, he held strategic human resources positions at Rhône-Poulenc Rorer, FMC Corp. and Shell Oil Co.

Recently, the company appointed Robert Crotty as the new executive vice president and legal counsel of INOVIO Pharmaceuticals. “Rob brings significant industry experience heading the legal function of several successful biotech companies,” said Hochberg. Mr. Crotty joined INOVIO after working at Nabriva Therapeutics, where he served as legal counsel and secretary.

Related: Caliber Associates Holds Senior Position For Sutro Biopharma

Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, editor-in-chief; and Stephen Sawicki, Editor-in-Chief – Hunt Scanlon Media


]]>
Graphex Group announces the creation of a subsidiary in the United States; appoints John DeMaio CEO | News https://ronbercume.com/graphex-group-announces-the-creation-of-a-subsidiary-in-the-united-states-appoints-john-demaio-ceo-news/ Mon, 20 Dec 2021 14:15:00 +0000 https://ronbercume.com/graphex-group-announces-the-creation-of-a-subsidiary-in-the-united-states-appoints-john-demaio-ceo-news/ ROYAL OAK, Mich., December 20, 2021 (GLOBE NEWSWIRE) – Graphex Group Limited, a global leader in graphene technologies and products used in the production of electric vehicle (EV) batteries and energy storage, is pleased to ” announce the formation of its US Subsidiary, Graphex Technologies LLC (Graphex), and the appointment of its new CEO. Graphex […]]]>


ROYAL OAK, Mich., December 20, 2021 (GLOBE NEWSWIRE) – Graphex Group Limited, a global leader in graphene technologies and products used in the production of electric vehicle (EV) batteries and energy storage, is pleased to ” announce the formation of its US Subsidiary, Graphex Technologies LLC (Graphex), and the appointment of its new CEO.

Graphex Group is one of the largest manufacturers of spherical graphite, a key material for the production of lithium-ion battery cells used to form layers of graphene in the anode of lithium-ion battery cells. It currently operates its high-volume manufacturing process and product technology, protected by 23 patents, for electric vehicles manufactured and sold in Asia. Graphex Group’s spherical graphite manufacturing plant is strategically located in Heilongjiang Province, a region rich in reserves of high-quality natural graphite. Lithium-ion batteries are one of the world’s most sought-after technological components, as they are an integral part of electric vehicles and energy storage solutions needed to drive clean energy transformation. They are also used in many other applications including personal electronic devices such as cell phones, laptops and many other household items.

Following its entry into the American market and the creation of a manufacturing plant in 2022, Graphex intends to capitalize on the global demand for lithium-ion batteries for electric vehicles and stored energy, in particular on the American and European markets. As both a technology and a manufacturing company, it will also continue to identify and develop future applications of graphene. The Company intends to construct a manufacturing facility in the United States capable of producing 20,000 to 50,000 tonnes of coated natural graphite anode material annually.

John DeMaio has been appointed CEO of Graphex Technologies and President of the Graphene division of Graphex Group Limited, the former of which represents the US entity. In his new role, DeMaio will lead the development and launch of key strategic alliances in North America and Europe to support the surging demand for advanced technologies in the electric vehicle and renewable energy sectors. DeMaio will expand the opportunities to establish supply chains in the United States and Europe to bring technology, employment opportunities and reliable supply to these high growth markets.

“As we continue to develop our graphene business in Asia, home to one of the fastest growing electric vehicle industries, the need for technologies supporting electric vehicles and renewable energy increases around the world.” , said Chan Yick Yan Andross, Managing Director and Director, Groupe Graphex Limited. “Now is the right time to expand our international reach. We are delighted to welcome John to our team to provide advice to the parent organization and lead Graphex Technologies LLC as we establish international supply chains and explore global partnerships, strategic alliances, scientific collaboration and potential. vertically integrate complementary businesses.

DeMaio has held leadership positions including President and CEO of JouleSmart Solutions; Managing Director of Siemens Smart Infrastructure; vice-president of MWH Global; Chief Operating Officer of Thompson Solar Technologies; and division head of SPG Solar. These roles range from successful startups to divisional and regional turnarounds in Fortune 50 companies. With over 20 years of experience in the energy and infrastructure industries, DeMaio has developed and commercialized several new technologies in emerging markets including photovoltaics, advanced waste-to-energy solutions and artificial intelligence platforms for objects.

“It’s an honor to join this progressive organization and lead this team of extremely intelligent professionals who understand exactly what business we are in and are committed to being the best at what we do,” said John DeMaio, CEO of Graphex Technologies LLC. “As a leading technology company providing R&D and product innovations in the field of electric vehicle battery technology and alternative energy production, storage and delivery, Graphex is ideally positioned for strong growth in markets outside of Asia. Our ability to provide superior graphite and graphene related products and technologies today – while continuously innovating and expanding our offerings in anticipation of the evolving needs of tomorrow – will make the Graphex Group a fundamental force in the global energy transition. About Graphex Group Limited Graphex Group Limited focuses on the development of technologies and products for the improvement of renewable energies, in particular the enrichment of spherical graphite and graphene, key components of EV batteries, lithium-ion batteries and other uses. Strategically located near the largest source of supply of high quality natural flake graphite in the world, the Graphex Group is currently one of the leading suppliers of specialized spherical graphite for the electric vehicle and renewable energy industries. It plans to secure and further expand the upstream supply chain and increase the delivery volume by 400% over the next three years to support the unprecedented proliferation of demand for batteries. Graphex holds 23 patents in areas such as products, production methods, machine design and environmental protection.

Safe Harbor Statement This press release is issued in accordance with Rule 135 of the Securities Act of 1933, as amended (the “Securities Act”), and does not constitute an offer to sell or the solicitation of an offer to sell. purchase, all titles. Any offer, solicitation or offer to buy, or sale of securities will be made in accordance with the registration requirements of the Securities Act.

Statements regarding the future expectations of the company, and all other statements contained in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbor rules thus created.

The above information contains information relating to the Company which is based on the beliefs of the Company and / or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate”, “estimate”, “expect”, “intend”, “plans”, “plans” and similar expressions, in relation to concerns the Company or its management, are intended to identify forward-looking statements. These statements reflect the Company’s current opinion regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties mentioned. If one or more of these risks or uncertainties materialize, or if the underlying assumptions turn out to be incorrect, actual results could differ materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each case, forward-looking information should be taken into account in the light of the accompanying significant warnings. Factors that could cause different results include, but are not limited to, the proper execution of internal plans, the impact of competitive pricing and services, and general economic risks and uncertainties.

Information from third-party sources identified in this release is based on reports published for such information and we have assumed the accuracy of such reports without investigation or independent investigation.

This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, including, but not limited to, its US deposit shares.

The information made available on the aforementioned Company website does not form part of any disclosure made or to be made by the Company regarding an offer to sell or the solicitation of an offer to buy securities of the Company and does not constitute part of any documents filed by the Company with the United States Securities and Exchange Commission.

Contact details: investrel@graphexgroup.com

Media inquiries FischTank PR graphex@fischtankpr.com


]]>
Samsung’s new Chinese team announces a restart of its strategy https://ronbercume.com/samsungs-new-chinese-team-announces-a-restart-of-its-strategy/ Sun, 19 Dec 2021 06:28:17 +0000 https://ronbercume.com/samsungs-new-chinese-team-announces-a-restart-of-its-strategy/ Samsung Electronics has reportedly launched a new team in China under the direct supervision of Vice President and CEO Han Jong-hee, signaling a change in its strategy to re-enter Asia’s largest market which is already dominated by local manufacturers . According to media reports, Samsung Electronics has launched a new operation, roughly translated by China […]]]>


Samsung Electronics has reportedly launched a new team in China under the direct supervision of Vice President and CEO Han Jong-hee, signaling a change in its strategy to re-enter Asia’s largest market which is already dominated by local manufacturers .

According to media reports, Samsung Electronics has launched a new operation, roughly translated by China Business Innovation Team. The unit is dedicated to companies ranging from mobile phones to semiconductor chips. Han, who was promoted to one of Samsung’s CEOs earlier in December, will take charge of its operations. Samsung Electronics declined to comment on the matter.

One wonders if Samsung would seek to reverse the downsizing trend in China in recent years.

Samsung’s Chinese operations had some 18,000 employees and executives in 2020, down 40% from 2018. Combined net sales of Chinese arms fell 12.5% ​​in the cited period to reach 37.8 trillion. won ($ 31.9 billion) in 2020, according to Samsung.

The decrease in presence stems from the stronger position of Chinese technology rivals in the market, coupled with geopolitical tensions, especially those in China and the United States.

In China, local smartphone brands have overtaken Samsung in terms of shipments, while a new locally produced foldable phone shows a technological advantage over Samsung in the high-end segment.

According to data compiled by industry intelligence provider Counterpoint Research, Chinese brands vivo, Oppo, Honor and Xiaomi absorbed 72% of China’s smartphone shipments, being the country’s top four smartphone suppliers during the third quarter.

Meanwhile, Samsung’s smartphone market share by shipment has barely exceeded 1% in China since 2018, compared to 20% recorded in 2013 and 2014. Along with Samsung, flagship iPhone maker Apple has seen its share market in China gradually decrease, from 16% in the fourth quarter of 2020 to 13% in the third quarter of 2021.

Also in India, Samsung conceded first place to Xiaomi by shipping smartphones for four consecutive quarters until September. Three of the top five models for Q3 2021 came from Xiaomi.

The Chinese cellphone maker, which produces the flagship phones Redmi and Mi, also overtook Samsung in monthly shipments in June to take the top spot, posing a challenge for the Korea-based tech leader and most the world’s largest smartphone maker by shipment so far, according to Counterpoint Research.

“Although Xiaomi is getting closer to Samsung in the second quarter of 2021 is an event to be reckoned with, it is not without precedent,” noted Harmeet Singh Walia of the Indian team at Counterpoint Research.

Meanwhile, Oppo’s entry into the foldable phone market, with its flagship Find N, is now gaining traction as their fold is “up to 80% less noticeable” on the handset when using the phone. the inner screen, compared to Samsung’s Galaxy Z Fold and Z Flip lineup, according to Pete Lau, Oppo’s chief product officer. Oppo will sell the product, with advanced foldable screen features, at two-thirds the price of Samsung’s foldable phones in China.

When it comes to the semiconductor industry, Samsung Electronics is keen to protect itself from the disruptions in the semiconductor supply chain that have hit global manufacturers due to trade tensions between the United States and China. Samsung bases its semiconductor line in Xi’an, central China, and its semiconductor packaging operations in Suzhou, a city near Shanghai.

Meanwhile, eyes are also on the de facto leadership of Samsung’s de facto leader Lee Jae-yong during the respite from Lee’s trial over allegations of breach of trust over his role in the merger of the companies. main subsidiaries Samsung C&T and Cheil Industries in 2015. China is one of the possible destinations for Lee’s long-awaited third trip abroad following an early release in August from a bribery conviction against the ex. -President Park Geun-hye, alongside a European country. Earlier this year, Lee visited the United States and the United Arab Emirates, his visit to the United States leading to a $ 17 billion deal in Texas to build a new foundry plant.

Lee’s last visit to China was to a semiconductor factory in Xi’an in May 2020. Xi’an is home to a semiconductor factory established in 2014, and Samsung has embarked on a project to increase its production capacity with a second production line. Samsung has announced capital expenditure of 8 trillion won just for a production line in Xi’an.

By Son Ji-hyoung (consnow@heraldcorp.com)


]]>
Samsung Elec to merge mobile and consumer electronics divisions By Reuters https://ronbercume.com/samsung-elec-to-merge-mobile-and-consumer-electronics-divisions-by-reuters/ Tue, 07 Dec 2021 00:35:00 +0000 https://ronbercume.com/samsung-elec-to-merge-mobile-and-consumer-electronics-divisions-by-reuters/ © Reuters. FILE PHOTO: The Samsung Electronics logo is seen on a dishwasher at its store in Seoul, South Korea, August 27, 2020. REUTERS / Kim Hong-Ji / File Photo By Joyce Lee SEOUL (Reuters) – Samsung Electronics (LON 🙂 Co Ltd said on Tuesday it would merge its mobile and consumer electronics divisions, as […]]]>


© Reuters. FILE PHOTO: The Samsung Electronics logo is seen on a dishwasher at its store in Seoul, South Korea, August 27, 2020. REUTERS / Kim Hong-Ji / File Photo

By Joyce Lee

SEOUL (Reuters) – Samsung Electronics (LON 🙂 Co Ltd said on Tuesday it would merge its mobile and consumer electronics divisions, as it focuses on growing its logic chip business.

The sweeping move is the latest sign of change at the world’s largest memory chip and smartphone maker, after Vice President Jay Y. Lee was released on parole in August following a corruption conviction. .

Head of visual display business Han Jong-hee has been promoted to vice president and co-CEO, and will lead the new merged division spanning mobile and consumer electronics.

Kyung Kye-hyun, CEO of Samsung Electro-Mechanics, has been appointed co-CEO of Samsung Electronics and will lead the chips and components division.

Samsung Group is focused on areas such as semiconductors, artificial intelligence, robotics and biopharmaceuticals, and plans to invest 240 trillion won ($ 206 billion) in these areas over the next three years.

The group’s flagship product, Samsung Electronics, aims to overtake TSMC to become the No. 1 in contract chip manufacturing by 2030.

Disclaimer: Fusion media would like to remind you that the data contained in this site is not necessarily real time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by the exchanges but rather by market makers. The prices may therefore not be exact and differ from the actual market price, which means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media assumes no responsibility for any business losses that you may incur as a result of the use of such data.

Fusion media or anyone involved with Fusion Media will not accept any responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.


]]>
Hill District development remains intact with new owners of Penguins https://ronbercume.com/hill-district-development-remains-intact-with-new-owners-of-penguins/ Tue, 30 Nov 2021 00:17:00 +0000 https://ronbercume.com/hill-district-development-remains-intact-with-new-owners-of-penguins/ THE TEAM AND THE CITY? SHELDON? >> CONSTRUCTION FOR THE LOWER HILL DEVELOPMENT HAS BEGUN AND THE MAYOR SAYS THE FUTURE OF THIS PROJECT IS SECURE WHO THE OWNER OF THE PENGUINS IS. >> THE REDEVELOPMENT OF THE MIDDLE AND UPPER HILL, THESE DIFFERENT TYPES OF AGREEMENTS WILL BE INTACT. THE ONLY DIFFERENCE WILL BE […]]]>


THE TEAM AND THE CITY? SHELDON? >> CONSTRUCTION FOR THE LOWER HILL DEVELOPMENT HAS BEGUN AND THE MAYOR SAYS THE FUTURE OF THIS PROJECT IS SECURE WHO THE OWNER OF THE PENGUINS IS. >> THE REDEVELOPMENT OF THE MIDDLE AND UPPER HILL, THESE DIFFERENT TYPES OF AGREEMENTS WILL BE INTACT. THE ONLY DIFFERENCE WILL BE WHO OWNS THE TEAM? >> THE FIRST TOWER OF THE NATIONAL BANK IS THE ANCHOR OF THIS MASSIVE INTELLIGENT PROJECT THAT STARTS IN LOWER HILANL D IT IS EXPECTED TO CONTINUE IN MIDDLE AND UPPER HLIL AS A REVITALIZATION PROJECT. THE HILL COMMUNITY DEVELOPMENT CORPORATION HAS CONCERNS ABOUT AFRO-AMERICANS BENEFITING FROM THE JOBS THAT WILL BE CREATED WITH THIS PROJECT. ESPECIALLY IN THE LOWER HILL OF THE BANK TOWER. SAY THIS, AND SCIPEFICALLY THE FENWAY SPORTS GROUP HAS BEGUN TO THINK ABOUT HOW THE PENGUINS ORGANIZATION CAN FULFILL ITS COMMITMENTS TO THE HILL DISTRICT COMMUNITY AS PART OF TRANSACTION AND ORGANIZATIONAL STRATEGY. NO MORE FROM MAYOR. >> EVERYTHING THEY FUCKED AND EVERYTHING HAS BEEN PROMISED, AND EVERYTHING FOR THE FUTURE WILL BE GUARANTEED. >> ALSO TODAY, HE T MAYOR SAYS HE WOULD BE M

Lower Hill development remains intact as new group of owners take control of Penguins

Mayor Bill Peduto said on Monday that massive development in the Lower Hill District will continue as the Pittsburgh Penguins organization is set to change ownership in the near future. development project starting in Lower Hill, with a first National Bank tower, office and commercial space, while extending into the community of Middle Hill and Upper Hill. Some of the features of the project include pledges of investments of up to $ 50 million over time in Middle Hill and Upper Hill, as well as job creation for African Americans in the businesses created in Lower Hill. where the bank tower is. However, the Hill Community Development Corp. suggests that these promises may not be as strong as those initially made by the Penguins, and encourages the Fenway Sports Group to follow through on the commitments “and in particular that the Fenway Sports Group has started to think about how the Penguins organize ation can fulfill all of its commitments to the Hill District community as part of the transaction and organizational strategy, ”Hill CDC President and CEO Marimba Milliones said in a written statement. Peduto said these commitments will be honored: “Everything they’ve fought for, and everything they’ve been promised and everything going forward will be guaranteed to them.” Fenway Sports Group, owners of the Boston Red Sox, concluded a deal with the Penguins that will give FSG a controlling stake in the hockey franchise. The deal, which would see Mario Lemieux and Ron Burkle part of the Pens ownership group, is pending approval by the NHL Board of Governors.

Mayor Bill Peduto said on Monday that massive development in the Lower Hill District will continue as the Pittsburgh Penguins organization is set to change ownership in the near future.

Watch the report from the old Civic Arena site: Click on the video player above.

This is an economic development project starting in Lower Hill, with a first National Bank tower, office and retail space, while extending into the community of Middle Hill and Upper Hill.

Some of the features of the project include pledges of investments of up to $ 50 million over time in Middle Hill and Upper Hill, as well as job creation for African Americans in businesses created in the region. Lower Hill where the bank tower is located.

However, the Hill Community Development Corp. suggests that these promises might not be as strong as initially stated by the Penguins, and encourages the Fenway Sports Group to follow through on the commitments “and in particular that the Fenway Sports Group has started to think about how the organization des Penguins can fulfill all of its commitments to the Hill District community as part of the transaction and organizational strategy, ”said Marimba Milliones, President and CEO of Hill CDC, in a statement.

Peduto said these commitments will be honored: “Everything they fought for, everything they were promised and everything going forward will be guaranteed to them.

Fenway Sports Group, owners of the Boston Red Sox, have reached a deal with the Penguins that will give FSG a controlling stake in the hockey franchise.

The deal, which would see Mario Lemieux and Ron Burkle part of the Pens ownership group, is pending approval by the NHL board of governors.


]]>
Pamplin Media Group – Charles: Washington Square regional plan doomed to ugly crystal ball https://ronbercume.com/pamplin-media-group-charles-washington-square-regional-plan-doomed-to-ugly-crystal-ball/ Tue, 23 Nov 2021 08:00:00 +0000 https://ronbercume.com/pamplin-media-group-charles-washington-square-regional-plan-doomed-to-ugly-crystal-ball/ John A. Charles Jr. is President and CEO of the Cascade Policy Institute, Oregon’s free market public policy research organization. Tigard City Council is in the process of adopting a new land use plan for the 827-acre area known as the Washington Square Regional Center. Once adopted, it will replace an existing plan approved in […]]]>


John A. Charles Jr. is President and CEO of the Cascade Policy Institute, Oregon’s free market public policy research organization.

Tigard City Council is in the process of adopting a new land use plan for the 827-acre area known as the Washington Square Regional Center. Once adopted, it will replace an existing plan approved in 1999.

If you didn’t know there was a “regional plan” for the Washington Square neighborhood, there’s a good reason: it was never implemented. The 1999 plan was based on the mythical concept of “transit-oriented development” and featured architectural renderings of 20-story towers at the mall, improved transit service, and bicycle and pedestrian bridges crossing the mall. ‘highway 217.

None of this had to do with reality, so it didn’t happen. The proposed new plan makes the same mistakes.

The whole concept of a regional center was invented by Metro planners when they drafted Conceptual Plan 2040, which was adopted in 1995. This plan was intended to ensure that the Portland area “would grow, not »Over a 45-year period, with transport investments focused on public transport, cycling and walking. The implementation was based on a cascade of large and small “centers”. At the top of the food chain were eight regional hubs, followed by dozens of smaller city centers and station communities clustered around light rail stops.

The eight regional centers are: Gateway, Downtown Hillsboro, Tanasbourne / AmberGlen, Downtown Beaverton, Washington Square, Downtown Oregon City, Downtown Gresham, and Downtown Clackamas. According to Metro, these neighborhoods are characterized by two- to four-story buildings served by high-quality public transport.

COURTESY PHOTO: CITY OF TIGARD - A proposal shows the plans for the Washington Square regional center plan.Although Metro held dozens of hearings on the 2040 concept and claimed to be gathering public input, planners never really cared what citizens thought. The overriding political objectives were: (1) to get people out of their cars; and (2) move most families from single-family homes to apartments located near transit lines.

As you might expect, it failed, and it failed spectacularly in Washington Square. The 1999 plan called for high-density development in Metzger’s unincorporated neighborhoods, which then were – and still are – characterized by single-family homes. The people who live in these houses have always been unhappy with being suppressed from existence by the planners.

The regional plan also assumed that too much of the mall’s land was wasted on parking and would have to be redeveloped into high-rise buildings. But people who shop at the mall think parking is important, and there has never been a viable plan to pay for dream rides.

When TriMet was planning the WES commuter train line, which opened in 2009, there was a lot of excitement about having a stop in Washington Square. But Hall Boulevard WES station is so far from Washington Square that it doesn’t matter. And since WES only runs in the mornings and afternoons, and not at all on weekends, it has never been plausible that the train will change travel behavior in this neighborhood.

Between 1995 and 2021, Metro, TriMet and the City of Portland conspired to waste billions of dollars in taxes building streetcars and streetcars in support of regional hubs, but the use of public transportation was not never became important. It was particularly low in the regional centers. TriMet’s ridership peaked in 2012 and declined steadily thereafter. Once the pandemic hit, transit ridership fell by more than half and did not recover.

The new Washington Square regional plan under consideration reduces the vision for high-rise towers, but still embraces the failing principles of “transit-oriented development.” The main objective is to increase the number of housing units, everywhere. But again, the plan ignores consumer preferences and market reality. The area is car oriented and includes low rise buildings because that is what most people want.

The reason land use plans tend to fail is that it’s impossible to know what is the best use for each piece of land. This can only be determined by the dynamic process of the market. We would all be better off if Tigard and other towns started repealing their zoning codes for “area plans” and simply allowed land to be developed based on what the market would support.

John A. Charles Jr. is President and CEO of the Cascade Policy Institute, Oregon’s free market public policy research organization. He can be contacted at This e-mail address is protected from spam. You need JavaScript enabled to view it..


You depend on us to stay informed and we depend on you to fund our efforts. Good local journalism takes time and money. Please support us to protect the future of community journalism.


]]>
Teva Announces New Organization Structure and Leadership Changes https://ronbercume.com/teva-announces-new-organization-structure-and-leadership-changes/ https://ronbercume.com/teva-announces-new-organization-structure-and-leadership-changes/#respond Sun, 03 Oct 2021 18:02:08 +0000 https://ronbercume.com/?p=98 JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE & TASE:TEVA) announced today a new organization and leadership structure aimed to achieve better commercial focus and drive value creation. The new structure will enable strategic alignment across the portfolio, across regions and between functions, leveraging scale, enhancing agility, extracting efficiencies and providing increased proximity to the markets. This […]]]>


JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE & TASE:TEVA) announced today a
new organization and leadership structure aimed to achieve better
commercial focus and drive value creation. The new structure will enable
strategic alignment across the portfolio, across regions and between
functions, leveraging scale, enhancing agility, extracting efficiencies
and providing increased proximity to the markets. This new structure
will be implemented effective immediately.

Kåre Schultz, Teva’s President and CEO, said, “Teva is taking decisive
and immediate action to address external pressures and internal
inefficiencies. Our new company structure will enable stronger alignment
and integration between R&D, operations and the commercial regions,
allowing us to become a more agile, lean and profitable company.”

Schultz continued, “We will focus on driving sustainable value creation.
The new management team will position Teva for turnaround in the short
to medium term. We are already working on a detailed restructuring plan
for Teva and will share it in mid-December. It remains our absolute
priority to stabilize the company’s operating profit and cash flow in
order to improve our financial situation, while being focused on
short-term revenue and cash generation, and at the same time, ensure we
deliver on our commitment to supply high-quality medicines to patients
around the world.”

New structure

  • The commercial business will no longer have two separate global groups
    for generics and specialty medicines, and will be integrated into one
    commercial organization, operating through three regions – North
    America, Europe and Growth Markets. Each of the regions will manage
    the entire portfolio – including generics, specialty and OTC – with
    full end-to-end P&L accountability. Some of the former global units
    will be integrated into the new structure, while others will be made
    redundant.
  • The former Generic R&D and Specialty R&D organizations will be
    combined into one global group with overall responsibility for all R&D
    activities – generic, specialty and biologics – maximizing ROI through
    better focus and efficiency.
  • A newly formed Marketing & Portfolio function will be responsible for
    overseeing the interface between regions, R&D and operations
    throughout all product lifecycle stages and optimizing generic and
    specialty portfolios across the therapeutic areas.
  • The new structure will enhance alignment and seamless integration
    between Teva’s Global Operations, the commercial regions, R&D and the
    Portfolio function, will increase productivity and simplify the
    organization.
  • The commercial structure will rely on one leaner supporting
    organizational infrastructure that includes Finance, Legal, HR, and
    Global Brand & Communications.

As a result of these changes, Dr. Michael Hayden, Dr. Rob Koremans and
Dipankar Bhattacharjee will retire from Teva, effective December 31,
2017.

New executive management team

Michael (Mike) McClellan is appointed Executive Vice
President, Chief Financial Officer
and will oversee the Finance
Group, Business Development, Investor Relations and Information
Technology. Previously, he served as Interim CFO and as
SVP & CFO Global Specialty Medicines. Prior to joining Teva, Mike was
the U.S. CFO at Sanofi.

Dr. Hafrun Fridriksdottir is appointed Executive Vice
President, Global R&D
. Previously, she served as President of
Global Generics R&D. Prior to joining Teva, Hafrun served as Senior Vice
President and President of Global Generics R&D in Allergan plc.

Brendan O’Grady is appointed Executive Vice President, North
America Commercial
. Brendan has previously served as Chief
Commercial Officer, Global Specialty Medicine, as interim head of Teva’s
European specialty business and as President and CEO for Teva’s North
America generics business and as VP US Market Access and Reimbursement.

Richard Daniell is appointed Executive Vice President,
European Commercial,
after having served as President and CEO, Teva
Generics Europe.

Gianfranco Nazzi is appointed Executive Vice President, Growth
Markets Commercial
. Gianfranco has previously served as President
and CEO of Growth Markets at the Global Generic Medicines group, and
prior to that he was he has served as Senior Vice President, Specialty
Medicines Europe.

Sven Dethlefs is appointed Executive Vice President, Global
Marketing & Portfolio
. He previously served as Global Head of
Respiratory Medicines and as Chief Operating Officer, Teva Global
Operations.

All appointments are effective immediately, while the retiring
executives will stay with Teva to support the transition until the end
of the year.

The following members of Teva’s executive management team will
continue in their current positions
:

Carlo de Notaristefani, Executive Vice President, Global Operations;

Iris Beck-Codner, Executive Vice President, Global Brand &
Communications;

Mark Sabag, Executive Vice President, Global Human Resources;

David Stark, Executive Vice President, Chief Legal Officer.

KÃ¥re Schultz concluded, “I would like to thank Dr. Michael Hayden, Dr.
Rob Koremans and Dipankar Bhattacharjee for their profound contributions
to Teva over the past decade and for their tireless dedication to the
many patients we serve.”

Bios of new appointments

Michael (Mike) McClellan has been serving as Teva Interim Group
CFO since July 2017. Prior to this role, he had served as SVP & CFO
Global Specialty Medicines since July 2015. Prior to joining Teva, Mike
was the U.S. CFO at Sanofi, where his career spanned nearly 20 years in
roles of increased responsibility in global finance and healthcare. Mr.
McClellan received his BSBA, Accounting & Economics from the University
of Missouri Trulaske College of Business.

Dr. Hafrun Fridriksdottir has been serving as Executive Vice
President, President of Global Generics R&D since February 2017, after
serving as Senior Vice President and President of Global Generics R&D
from 2016. Prior to joining Teva, from 2015 to 2016, Ms. Fridriksdottir
served as Senior Vice President and President of Global Generics R&D in
Allergan plc. From 2002 to 2015, she held positions of increasing
responsibility within the Actavis Group, including Senior Vice
President, R&D. From 1997 to 2002, Ms. Fridriksdottir served as
Divisional Manager of Development at Omega Pharma, until its merger with
Actavis. Ms. Fridriksdottir started her career as a scientist for 2
years at a research and development company owned by Pharmacia in
Sweden, after receiving an MS degree in pharmacy and a Ph.D. in physical
pharmacy from the University of Iceland.

Brendan O’Grady has been serving as Chief Commercial Officer,
Global Specialty Medicine division since Aug 2016. In addition, he
currently serves as the interim head of Teva’s European Specialty
business. Prior to these roles, Mr. O’Grady held the position of
President and CEO for Teva’s North America generic business in 2015 and
held various senior roles since he joined Teva in 2011 as Regional
Account Manager. Prior to joining Teva, Mr. O’Grady spent 10 years with
Sanofi predecessor companies in a variety of commercial and medical
affairs roles that began in field sales. He received his B.S. from
Geneseo State University, NY in Management Science/Marketing and holds
an M.B.A. from Baker University in Baldwinsville, Kansas.

Gianfranco Nazzi has been serving as President & CEO of Growth
Markets, Global Generic Medicines Group since March 2017. Mr. Nazzi
joined Teva as Senior Vice President Specialty Medicines Europe in 2014.
Prior to joining Teva, he served 7 years at AstraZeneca in various
senior roles, including Sales and Marketing Vice President Europe,
Global Vice President Respiratory, General Manager of the Balkans and
Vice President Primary Care in Italy. At GlaxoSmithKline he served for
two years as BU Director Metabolic & Cardiovascular and at Eli Lilly and
Company he served for 5 years in various sales and marketing roles in
both Italy and the US. He began his career at Danieli. Mr. Nazzi
received his BA degree in economics from the University of Udine, and
his Masters degree in Management Studies from SDA Bocconi.

Richard Daniell has been serving as President and Chief Executive
Officer, Teva Generics Europe since Dec 2016. Prior to that, he had
served as Chief Integration Officer Leading Actavis-Teva Integration
since Sep 2015 after holding various senior roles, including Chief
Operating Officer, Growth Markets and Regional General Manager for Teva
in the UK and Ireland from 2012 through 2014. Mr. Daniell joined Teva as
Senior Director Teva UK Limited in 2006, following the acquisition of
IVAX Pharmaceuticals UK. Prior to joining Teva, he served three years at
IVAX Pharmaceuticals UK as Director of Generics. Mr. Daniell received
his BSc in chemistry from the University of Auckland.

Sven Dethlefs has been serving as Global Head of Respiratory
Medicines, Global Specialty Medicines since January 2016. Prior to that,
he had served as Chief Operating Officer, Teva Global Operations, since
October 2013. Mr. Dethlefs joined Teva as General Manager, Teva Germany
in 2008. Prior to joining Teva, he served for over 11 years as a partner
at McKinsey & Company. Mr. Dethlefs received his PhD in biochemistry
from the FU Berlin/Pasteur Institute Paris.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200 million
patients in over 60 markets every day. Headquartered in Israel, Teva is
the world’s largest generic medicines producer, leveraging its portfolio
of more than 1,800 molecules to produce a wide range of generic products
in nearly every therapeutic area. In specialty medicines, Teva has the
world-leading innovative treatment for multiple sclerosis as well as
late-stage development programs for other disorders of the central
nervous system, including movement disorders, migraine, pain and
neurodegenerative conditions, as well as a broad portfolio of
respiratory products. Teva is leveraging its generics and specialty
capabilities in order to seek new ways of addressing unmet patient needs
by combining drug development with devices, services and technologies.
Teva’s net revenues in 2016 were $21.9 billion. For more information,
visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:

  • uncertainties relating to the potential benefits and success of our
    new structure and recent senior management changes as well as the
    potential success and our ability to effectively execute a
    restructuring plan;
  • our generics medicines business, including: that we are
    substantially more dependent on this business, with its significant
    attendant risks, following our acquisition of Allergan plc’s worldwide
    generic pharmaceuticals business (“Actavis Generics”); our ability to
    realize the anticipated benefits of the acquisition (and any delay in
    realizing those benefits) or difficulties in integrating Actavis
    Generics; the increase in the number of competitors targeting generic
    opportunities and seeking U.S. market exclusivity for generic versions
    of significant products; price erosion relating to our generic
    products, both from competing products and as a result of increased
    governmental pricing pressures; and our ability to take advantage of
    high-value biosimilar opportunities;
  • our specialty medicines business, including: competition for our
    specialty products, especially Copaxone
    ®, our
    leading medicine, which faces competition from existing and potential
    additional generic versions and orally-administered alternatives; our
    ability to achieve expected results from investments in our product
    pipeline; competition from companies with greater resources and
    capabilities; and the effectiveness of our patents and other measures
    to protect our intellectual property rights;
  • our substantially increased indebtedness and significantly
    decreased cash on hand, which may limit our ability to incur
    additional indebtedness, engage in additional transactions or make new
    investments, and may result in a downgrade of our credit ratings;
  • our business and operations in general, including: our ability to
    develop and commercialize additional pharmaceutical products;
    manufacturing or quality control problems, which may damage our
    reputation for quality production and require costly remediation;
    interruptions in our supply chain; disruptions of our or third party
    information technology systems or breaches of our data security; the
    failure to recruit or retain key personnel;the restructuring of our
    manufacturing network, including potential related labor unrest; the
    impact of continuing consolidation of our distributors and customers;
    variations in patent laws that may adversely affect our ability to
    manufacture our products; our ability to consummate dispositions on
    terms acceptable to us; adverse effects of political or economic
    instability, major hostilities or terrorism on our significant
    worldwide operations; and our ability to successfully bid for suitable
    acquisition targets or licensing opportunities, or to consummate and
    integrate acquisitions;
  • compliance, regulatory and litigation matters, including: costs and
    delays resulting from the extensive governmental regulation to which
    we are subject; the effects of reforms in healthcare regulation and
    reductions in pharmaceutical pricing, reimbursement and coverage;
    potential additional adverse consequences following our resolution
    with the U.S. government of our FCPA investigation; governmental
    investigations into sales and marketing practices; potential liability
    for sales of generic products prior to a final resolution of
    outstanding patent litigation; product liability claims; increased
    government scrutiny of our patent settlement agreements; failure to
    comply with complex Medicare and Medicaid reporting and payment
    obligations; and environmental risks;
  • other financial and economic risks, including: our exposure to
    currency fluctuations and restrictions as well as credit risks; the
    significant increase in our intangible assets, which may result in
    additional substantial impairment charges; potentially significant
    increases in tax liabilities; and the effect on our overall effective
    tax rate of the termination or expiration of governmental programs or
    tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 20-F for the
year ended December 31, 2016 (“Annual Report”), including in the section
captioned “Risk Factors,” and in our other filings with the U.S.
Securities and Exchange Commission, which are available at
www.sec.gov
and
www.tevapharm.com.
Forward-looking statements speak only as of the date on which they are
made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You
are cautioned not to put undue reliance on these forward-looking
statements.


]]>
https://ronbercume.com/teva-announces-new-organization-structure-and-leadership-changes/feed/ 0
Serta Simmons Bedding announces leadership changes and streamlines organizational structure https://ronbercume.com/serta-simmons-bedding-announces-leadership-changes-and-streamlines-organizational-structure/ https://ronbercume.com/serta-simmons-bedding-announces-leadership-changes-and-streamlines-organizational-structure/#respond Tue, 06 Apr 2021 07:00:00 +0000 https://ronbercume.com/serta-simmons-bedding-announces-leadership-changes-and-streamlines-organizational-structure/ Serta Simmons Bedding (SSB) recently announced organizational improvements, including changes to its leadership team, as part of its transformation and growth strategy. More specifically, Melanie Huet (formerly Chief Marketing Officer and EVP of Marketing and Innovation) will assume the role of Chief Commercial Officer of SSB, and Shelley Huff (formerly CEO of Tuft & Needle, […]]]>




Serta Simmons Bedding (SSB) recently announced organizational improvements, including changes to its leadership team, as part of its transformation and growth strategy. More specifically, Melanie Huet (formerly Chief Marketing Officer and EVP of Marketing and Innovation) will assume the role of Chief Commercial Officer of SSB, and Shelley Huff (formerly CEO of Tuft & Needle, EVP of Direct to Consumer) will become Chief of SSB Head of operations. Huet and Huff will retain their former titles of Chief Marketing Officer and CEO of Tuft & Needle, respectively, continue to serve on the company’s management team and report to SSB Chairman and CEO David Swift.

“We are relentless in our quest to help people sleep better through consumer-inspired innovation, a digitally driven mindset, our commitment to exceptional service and an exceptional team that always strives to raise the bar, ”said David Swift, President and CEO. of Serta Simmons bedding. “Both Melanie and Shelley have had a huge impact on our business during their time with the company. I look forward to working with them as we continue in this pursuit and accelerate our growth strategy. “

Huet has been instrumental in developing SSB’s brand portfolio over the past two years and has led the company’s transformation to a consumer-centric organization. As Chief Commercial Officer, she will lead a larger and unified team that brings together sales, marketing and innovation functions. She will work in partnership with Director of Sales Derek Miller to accelerate e-commerce growth, strengthen SSB’s omnichannel approach and accelerate time to market. Huet joined SSB in 2019 after holding various marketing and sales positions at The Kraft Heinz Company, Kimberly-Clark and Unilever.

Huff has been instrumental in the development of SSB’s Direct-to-Consumer Selling (DTC) business across its brand portfolio and in the growth of the Tuft & Needle brand. As Chief Operating Officer, she will oversee the company’s supply chain and company-wide customer experience teams, and will continue to lead the business operations (DTC) and the Tuft & Needle brand. Under Huff’s leadership, this expanded operations team will strengthen the digitally-focused corporate mindset and better leverage data and technology to drive growth across the enterprise. Huff joined SSB in July 2020 as CEO of Tuft & Needle and Executive Vice President of DTC after holding several leadership roles at Walmart US and Walmart eCommerce, including as President and CEO of Hayneedle.com.

Bob Hellyer, former Director of Supply Chain, will assume the new role of Executive Vice President of Strategic Initiatives, designed to leverage his deep industry expertise and strong relationships across SSB’s value chain. . He will also support the Sales team in accelerating disruptive innovation.

The digital-centric approach that underpins the company’s customer-centric growth strategy requires nurturing, leveraging and nurturing the talent of existing team members, as well as recruiting new ones. talents in key roles. Two new leaders will join Huff’s operations team to continue driving SSB’s digital transformation:

Cream Pepito joins SSB as Senior Vice President and CTO for DTC, responsible for leading technology strategy for SSB’s DTC business, including Marketing Platform and Technology. Pepito recently worked with Northwestern Mutual where she led high performing teams responsible for their technology solutions. Pepito has extensive experience leading various technology transformations for financial services, financial technology, logistics and manufacturing companies.

Bhavani Subramaniam joins SSB as Senior Vice President, Integrated Supply Chain, and is responsible for the company’s DTC supply chain, corporate logistics and warehousing, as well as sales and operations planning. Subramaniam joins SSB with over 20 years of experience in strategic and operational supply chain leadership roles in the retail and consumer staples industries, most recently at Walmart.


About Serta Simmons Bedding, LLC: Serta Simmons Bedding, LLC is a leading sleep company and one of the largest manufacturers, distributors and suppliers of mattresses and sleep solutions in North America. Atlanta-based SSB owns and operates two of the best-selling bedding brands in the mattress industry: Serta®, which has five other independent licensees, and Beautyrest®. Brands are distributed through national, hotel, regional and independent retail channels across North America. SSB also owns the Simmons® and Tuft & Needle® brands of direct-to-consumer mattresses. SSB operates 27 factories in the United States and Canada. For more information on SSB and its brands, visit www.sertasimmons.com.

Furniture industry news and in-depth magazine articles for furniture retail, furniture manufacturers and furniture distributors.

Read more articles from Nic Ledoux


]]>
https://ronbercume.com/serta-simmons-bedding-announces-leadership-changes-and-streamlines-organizational-structure/feed/ 0